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Abstract
Transcatheter aortic valve replacement (TAVR) is a minimally invasive alternative to conventional aortic valve replacement in
symptomatic patients with severe aortic stenosis and contraindications to surgery. The procedure has shown to improve patient’s
quality of life and prolong short- and mid-term survival in high-risk individuals, becoming a widely accepted therapeutic option
which has been integrated into current clinical guidelines for the management of valvular heart disease. Nevertheless, not every
patient at high-risk for surgery is a good candidate for TAVR. Besides clinical selection, which is usually established by the Heart
Team, certain technical and anatomic criteria must bemet as, unlike in surgical valve replacement, annular sizing is not performed
under direct surgical evaluation but on the basis of non-invasive imaging findings. Present consensus document was outlined by a
working group of researchers from the European Society of Cardiovascular Radiology (ESCR) and aims to provide guidance on
the utilisation of CT and MR imaging prior to TAVR. Particular relevance is given to the technical requirements and
standardisation of the scanning protocols which have to be tailored to the remarkable variability of the scanners currently utilised
in clinical practice; recommendations regarding all required pre-procedural measurements and medical reporting standardisation
have been also outlined, in order to ensure quality and consistency of reported data and terminology.
Key Points
• To provide a reference document for CT and MR acquisition techniques, taking into account the significant technological
variation of available scanners.
• To review all relevant measurements that are required and define a step-by-step guided approach for the measurements of
different structures implicated in the procedure.
• To propose a CT/MR reporting template to assist in consistent communication between various sites and specialists involved in
the procedural planning.
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ESCR European Society of Cardiovascular
Radiology
LAO Left anterior oblique
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LVOT Left ventricular outflow tract
OCA Ostia of coronary arteries
PAVR Percutaneous aortic valve replacement
RAO Right anterior oblique
SE Self-expandable valves
SOV Sinuses of Valsalva
SSFP Steady state free precession
STJ Sinotubular junction
TAVR or TAVI Aortic valve replacement or implantation
THV Transcatheter heart valves
Introduction
Elective surgical aortic valve replacement (AVR) is considered
the most effective treatment for advanced aortic valve stenosis
(AS), significantly improving symptoms and survival in com-
parison with individuals who refused or could not undergo an
invasive surgical procedure. Despite a reported mortality rate of
50% in the first 2 years for untreated patients, 30–40% of indi-
viduals could not receive curative treatment, deemed to be in-
eligible to surgery because of the high peri-operative risk [1, 2].
In response, new procedural options have emerged, based on
the development of transcatheter therapies with specific aortic
valve prostheses that can be transported to the aortic root using
a non-surgical endovascular, transaortic or transapical approach.
Once in place, these bioprosthetic valves or transcatheter heart
valves (THVs) functionally replace the native valve by displacing
it to the aortic root wall during deployment. This procedure is
named transcatheter aortic valve replacement or implantation
(TAVR or TAVI) or percutaneous aortic valve replacement
(PAVR) and was introduced in 2002 [3]. An illustrative guide
explaining the procedure for a self-expandable valve is displayed
in movie 1.
Nevertheless, not every patient who refused or at high-risk
for surgery is a good candidate for TAVI. Besides clinical
selection, certain technical and anatomic criteria must be met
as, unlike in surgical valve replacement, annular sizing is not
performed under direct surgical inspection but on the basis of
non-invasive imaging findings.
It has been estimated that annually about 27,000 individ-
uals with AS potentially fulfil eligibility criteria for TAVI in
Europe and North America, with obvious economic, clinical
and social implications emphasising the importance of an ad-
equate candidate selection [4, 5].
The present consensus document was outlined by a working
group of radiologists and researchers from the European
Society of Cardiovascular Radiology (ESCR) and aims to pro-
vide guidance on the execution and reporting of CT and MR
imaging prior to TAVI. Particular relevance will be given to the
technical requirements and standardisation of the scanning pro-
tocols which have to be tailored to the considerable variation of
the scanner technology currently utilised in clinical practice;
recommendations regarding standardised measurements and
medical reporting will also be outlined, in order to ensure qual-
ity and consistency of reported data and terminology.
Heart valve team
Consensus statement
& The Heart Valve Team supervises and discusses all aspect
of the TAVI selection process. A radiologist forms an in-
tegral part of this team.
The workup of a patient candidate for TAVI is a complex and
multifactorial process. Beyond patient selection and evaluation,
many factors contribute to the final success of the entire procedure,
such as team training and experience, procedural performance,
complication management, and post-procedural follow-up.
Therefore, it is recommended that all centres performing
TAVI procedures have extensive experience as a heart valve
centre including the availability of a dedicated Heart Valve
Team composed of experts in their respective field. Their task
is to supervise every aspect of the decision-making progress and
to assess individual patient risk for the different available treat-
ment options, with a shared decision-making approach for the
optimal therapeutic option. As such, the final decision regarding
a TAVI procedure must rely on the combination of all available
clinical data and imaging data from different modalities.
As non-invasive CT and MR imaging delivers essential
information necessary for proper patient selection and proce-
dural success, an experienced radiologist must form an inte-
gral part of the core team, combining clinical and technical
knowledge and discussing all relevant CT (or MR) imaging
findings with the rest of the team [6].
Indications for TAVI
Consensus statement
& TAVI is primarily targeted at high-risk non-surgical pa-
tients with severe AS. Recent trials results indicate a po-
tential expansion to intermediate-risk patients, as further
evidence is gathered.
In the last decade, TAVI has emerged as a transformational
technology providing new therapeutic options for selected
adult patients with severe AS. As intended, TAVI is approved
by different societies to be used in patients with severe symp-
tomatic AS at high prohibitive surgical risk and a life expec-
tancy of more than 1 year [7–10] (Table 1). The EuroSCORE
II [11] and/or the Society of Thoracic Surgeon (STS) risk
score [12] is employed to predict the procedural risk of
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surgical valve replacement. High-risk surgery corresponds to
a EuroSCORE II > 15–20% or STS score > 8–10%.
However, results of recent trials indicate a potential expan-
sion of TAVI indications to patients with an intermediate sur-
gical risk, applicable to both self-expandable and balloon-
expandable valves [8, 10, 13, 14]. This is also commented
on in the latest European Society of Cardiology guidelines
[7, 15]. This reflects the accumulation of data regarding its
efficacy and non-inferiority compared with a surgical ap-
proach in this patient category. Nevertheless, the final decision
regarding the therapeutic procedure is not simply based on a
risk score but is the end result of the deliberations by the Heart
Valve Team regarding the risk and benefits of all possible
interventions, especially in the intermediate-risk group. Also,
concerns remain regarding the long-term durability of THV,
an important point to consider when applying this technique in
a younger, lower risk population.
Other indications, including the use in low-risk patients and
the application of THV to treat bicuspid aortic valve disease and
aortic regurgitation, are currently under investigation.
Nevertheless, lack of high-quality data regarding the mentioned
long-term performance of THV and together with other on-
going issues like prevalence of post-procedural paravalvular
leakage and conduction disturbances with subsequent need
for pacemaker implantation remain important obstacles.
Therefore, a TAVI procedure in these conditions is not recom-
mended in routine clinical practice.
A relatively new application for TAVI is the treatment of a
failing surgical biological aortic valve prosthesis: the so-called
valve-in-valve procedure. This option is particularly beneficial
for high-risk individuals who underwent previous valvular
surgery. This procedure consists of placing a TAVI prosthesis
within a degenerated surgical bioprosthetic valve [16].
Diagnosis of severe aortic valve stenosis
Consensus statement
& The diagnosis and grading of severe aortic valve stenosis
relies on the patients’symptoms and imaging data regard-
ing aortic valve anatomy & hemodynamics.
& This imaging data is commonly acquired using Doppler
echocardiography.
& Quantification of the aortic valve calcification load
based on CT for diagnostic purposes is only necessary
in selected patients with a discordant result on Doppler
echocardiography.
& MRI can be used for quantification of the aortic valve
opening area and transvalvular velocities using
planimetry and phase contrast imaging with simulta-
neous LV ejection fraction calculation
Although, as previously discussed, indications for TAVI
are expanding; the main indication for TAVI remains severe
symptomatic aortic stenosis in high-surgical-risk patients.
Transthoracic echocardiography is the primary imaging
tool to diagnose AS, to confirm its presence, determine its
severity and deliver both anatomical and functional informa-
tion. Quantitative and qualitative data are provided using
Doppler techniques, resulting in an assessment of AS severity.
Table 1 Currently accepted clinical indications to TAVI summarised from the ESC/EACTS and AHA/ACC guidelines and from recently updated
ACC/AHA expert consensus decision pathway [7, 9]
ACC/AHA* ESC/EACTS^
Approach to care and clinical
decision-making:
To be established by a shared decision of local heart team To be made by a “heart team” with specific expertise in
VHD
Indications to the procedure: Recommended in patients with indication to intervention
for AS combined with a prohibitive surgical risk and a
predicted post-procedural survival > 12 months
Indicated in patients with severe AS and contraindication
to surgery, with an estimated life expectancy > 1 year
and an expected improvement of QoL by TAVI
General contraindications: Overall procedural risks and contraindications based on
scores evaluating patient’s frailty and disability plus
cognitive and physical function
General absolute contraindications include the absence
of a local “heart team” and/or an on-site cardiac
surgery facility
Importance of comorbidities: Procedure considered futile if life expectancy < 1 year
and/or survival with benefit < 25% at 2 years (i.e.
lack of improvement in NYHA or CCS functional
classes, quality of life or life expectancy)
Contraindicated In presence of extra-aortic valvular
disease that can be treated only by surgery and/or in
presence of an estimated life expectancy < 1 year
and/or unlikely post-procedural improvement of QoL
Anatomic contraindications: Non-specified (considered part of the clinical
decision-making process performed by local heart
team)
Inadequate annulus sizing (i.e. < 18 mm and a 29 mm)
Intracavitary thrombus, endocarditis, risk of coronary
ostium obstruction and ascending aorta/arch unstable
atheromasia
Inadequate vascular access
*ACC/AHA: American College of Cardiology/American Heart Association
^ESC/EACTS: European Society of Cardiology/European Association of Cardio-Thoracic Surgery
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In the case of normal transaortic volume flow rate, the best
characterisation of hemodynamic severity is achieved by the
assessment of the transaortic maximum velocity, mean pressure
gradient and aortic valve opening area (AVA). The maximum
transaortic velocity is measured using continuous wave Doppler
and the mean pressure gradient calculated based on a tracing of
the Doppler signal. AVA is not measured directly but calculated
using the continuity equation. In severe high-gradient AS, the
maximal aortic velocity is 4.0 m/s or higher and the mean
transaortic gradient is ≥ 40 mmHg. The aortic valve area is
≤ 1.0 cm2, but it may be larger under certain conditions.
However, two different categories of severe AS may exist
where transaortic volume flow rate is low. Left ventricle sys-
tolic dysfunction with low left ventricle ejection fraction
(LVEF) defines a low-flow/low-gradient severe AS subgroup.
Furthermore, the presence of a small hypertrophied left ventri-
cle with a low stroke volume and normal LVEF points to
paradoxical low-flow severe AS. In the case of reduced
LVEF, dobutamine stress echocardiography can be used to
assess whether LVEF can increase with a resultant increased
transaortic flow and increased aortic velocity to more than the
4.0 m/s threshold. Overall, the final diagnosis of severe AS in
these conditions, and therefore the potential need for TAVI,
may be difficult to establish using only echocardiography.
While exact quantification of aortic valve calcification load
is not routinely done in most centres, it may be considered
when Doppler echocardiography results are discordant with
the presumed diagnosis of AS. In such patients, quantification
of aortic valve calcification using the Agatston method, based
on a non-contrast CT, can be problem-solving, as AS severity
is associated with the load of valve calcification and provides
additional diagnostic value beyond clinical and Doppler echo-
cardiographic assessment [17, 18].
Different cut-off Agatston score values that make severe
AS likely have been proposed as ≥ 2000 for men and ≥ 1200
for women, as women have more severe AS for the same
calcium load compared with men [19, 20]. Scores of ≥ 3000
for men and ≥ 1600 for women are considered to make AS
very likely [21]. The latter thresholds are probably based on
the study by Clavel et al, in which these values give an ap-
proximately 95% positive predictive value for severe AS [18].
The same CT protocol is commonly similar to the one used for
Calcium scoring of the coronary arteries that by convention is
performed at 120 KV and with 3-mm thickness axial recon-
structions. Only the calcifications on the aortic valve leaflets
are to be included in the calculation [17]. Although direct
planimetry of the AVA on systolic CTA correlates with
Doppler-derived AVA, there is currently no direct role in the
diagnostic pathway for severe AS [22].
Alternatively, MRI can be used for assessment of aortic
valve stenosis in the following ways: direct aortic valve open-
ing areameasurement using planimetry using in-plane systolic
images; phase contrast velocity mapping for calculation of
pressure gradients over the valve and left ventricular function
from routine SSFP cine sequences [23]. Multiple double-
oblique parallel slices in plane with the valve should be ac-
quired to select the optimal phase for AVA measurement
(phase with maximum opening of the valve, measured at the
smallest orifice). Phase contrast flow calculations can result in
an underestimation of the flow compared with echocardiogra-
phy due to inherent differences between the two techniques
and can also be influenced by turbulent flow. Furthermore,
planimetry can be difficult in heavily calcified valves.
Pre-procedural comorbidities and incidental
findings
Consensus statement
& CT must not be routinely used for pre-procedural evaluation
of coronary artery disease. However, as technology evolves,
it can be used for this indication on a case-by-case basis and
according to local expertise and available equipment and
mainly to exclude significant coronary stenosis.
& Repercussions of incidental findings, including the presence
of malignancy, must be evaluated by the Heart Valve Team
on a case-by-case basis with regards to their influence on
procedural success and prognosis. Every finding that can
influence the procedure and its outcome must be reported.
Outside the diagnosis of severe AS, the assessment of co-
morbidities is of pivotal importance and needs a careful case-
by-case analysis. Given the advanced age, frail condition and
varying pre-existing conditions of TAVI candidates, a careful
multidisciplinary analysis is needed not only to assure proce-
dural eligibility but also to assess the likelihood of post-
procedural functional improvement and enhanced quality of
life [24]. In this document, we will focus on the contributions
of the radiologist.
Coronary artery disease is common (40–75%) in patients
undergoing TAVI and, in the absence of up-to-date informa-
tion regarding the status of the coronary arteries (no longer
than 3 months old), further investigation is needed [25]. In
general, coronary artery evaluation is commonly performed
using a classic invasive angiography. It is, currently, not rec-
ommended to routinely use CT for the pre-procedural evalu-
ation of the coronary arteries as the investigated population is
less suitable (prevalence of extensive coronary artery calcifi-
cations and cardiac arrhythmia) for coronary CT scanning.
Nevertheless, given advances in CT technology with increas-
ingly reliable image quality under a wider spectrum of condi-
tions, CT may be considered on a case-by-case basis to ex-
clude obstructive coronary artery disease, based on the locally
available equipment and expertise. An additional benefit of
CT is that it can allow concomitant evaluation of the coronary
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artery status together with the other necessary pre-procedural
measurements in a single CT examination and intravenous
contrast administration, as such limiting potential contrast-
induced nephrotoxicity.
Evaluation of non-vascular findings is an integral part of
the radiology report, and clinically significant incidental find-
ings have been reported in up to 25% of TAVI candidates [26].
Given the dismal prognosis of untreated severe AS, important
incidental findings like unexpected malignancy must be eval-
uated on a case-by-case basis by the Heart Valve Team, con-
sulting other relevant physicians and all available clinical data.
Incidental findings with immediate impact on the procedure,
e.g. obstruction along the possible access routes, have to be
highlighted in the radiology report as they may influence pro-
cedure eligibility.
Types of valvular devices and access sites
Consensus statement
& Balloon-expandable and self-expandable valves have dif-
ferent physical properties and possible access strategies.
Therefore, sizing algorithms are not simply interchange-
able and do not follow specific guidelines.
& The choice for a valve type mainly depends on the expe-
rience of the Heart Valve Team with a particular valve,
and on the available access routes.
All current clinically implemented THVs fall into two cat-
egories: balloon-expandable (BE) or self-expandable (SE)
valves [19]. A BE valve will expand using the radial strength
of the accompanying balloon and commonly force its circular
design on the oval-shaped annular morphology. Conversely, a
SE valve will deploy until it encounters the resistance of the
annular wall, conforming itself to the mostly oval-shaped
anatomy of the aortic annulus. This difference in physical
properties and consequently post-procedural morphology of
the THV implies that sizing algorithms are not interchange-
able between balloon- and self-expandable valves.
The most commonly used THVs are the BE SAPIEN range
(currently SAPIEN S3) from Edwards LifeSciences (Irvine,
Calif), and the SE Corevalve from Medtronic (Minneapolis,
Minn), now replaced by the newer Evolut platform (Fig. 1). A
detailed overview of the properties of these most commonly
used THV is given in Table 2. Both systems are approved in
Europe and in the USA for use in patients with severe symp-
tomatic AS who are considered to be at high surgical risk or
who declined for surgery owing to excessive risk.
These devices cover a combined aortic annular diameter
range of 16–30 mm, thereby allowing application in the vast
majority of patients. Also, they have different physical prop-
erties, potential access routes for delivery and choice of
delivery systems. All these factors may come to play a role
in the final choice of valve and delivery route.
There are currently no guidelines regarding the choice be-
tween self-expandable and balloon-expandable valves. In gen-
eral, many centres acquire experience using mainly one type
of valve in order to achieve the highest procedural success.
Selection of a valve typemainly depends on the range of valve
sizes available, the dimensions of the delivery device versus
the native vessels and the possible access routes.
There are some indications that a SE valve may be prefer-
able in an extremely oval-shaped annulus or a low implanta-
tion of coronary ostia. Conversely, a BE device can be con-
sidered when patients have a dilated ascending aorta
(> 43 mm) or severely angulated aorta (aortoventricular angle
> 70°) [27]. Despite wide diffusion and favourable outcomes
using the first generation of THV, some limitations remain.
These include, among others, the use of larger delivery sys-
tems increasing the risk for haemorrhagic and other vascular
complications during endovascular transportation and a per-
centage of patients with annular dimensions outside the appli-
cable range of these devices. Other complications such as
post-procedural paravalvular regurgitation and conduction
disturbances are multifactorial, but seem in part also linked
to the type of THVused (e.g. more conduction disturbances in
SE valves) [28, 29]. Additionally, none of the first-generation
devices could be repositioned, requiring implantation of a sec-
ond prosthesis or referral for surgery in case of unsatisfactory
positioning [21].
Therefore, various new THVs are being developed by dif-
ferent biomedical companies to overcome the drawbacks of
the first-generation TAVI devices and are in varying states of
large-scale clinical testing and official approval [30]. As an
example, while both SE and BE THV valves can be implanted
using an endovascular approach, only the SAPIEN valve was
the first to have the option of a transapical approach,
bypassing heavily calcified or tortuous/stenotic native arteries.
Therefore, recently newer SE systems have been introduced in
the market to take specific advantage of a transapical approach
including the Engager, JenaValve and Acurate valves [31].
Summarising physical properties, strengths and weaknesses
of these new-generation devices would go beyond the scope
of this document. A brief overview of last generations’ de-
vices is displayed in Table 3.
Standardisation of scanning protocols
Consensus statement
& The CTacquisition protocol should at least include a con-
trast enhanced ECG-gated or triggered scan of the aortic
root reconstructed with 1.0 mm or less slice thickness,
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preferably with several reconstructed phases but at least
including a systolic phase.
& A contrast enhanced CT scan with a scan range that at
least extends from the subclavian arteries to the
superficial femoral arteries at the level of the femoral
head is required.
& Both scans may be obtained from a single acquisition but
in most cases two separate acquisitions (one for the aortic
Fig. 1 CT images of a Medtronic self-expandable Corevalve (a) and
Edwards Lifesciences balloon-expandable Sapien valve (d). After
deployment, a self-expandable valve will conform itself to the normal
annular contour, acquiring an oval cross-sectional morphology (b).
Compared with a balloon-expandable valve, the self-expandable
Corevalve is larger in size and contains an inflow (I), waist (w), and
outflow (O) functional part (c). This outflow part is by design intended
to extend into the ascending aorta, covering but not obstructing the
coronary ostia. The balloon-expandable Sapien valve (d) is shorter,
with a mostly circular cross-sectional contour after deployment (e) as it
forces this circular morphology on the annulus through the radial forces
of the expanding balloon. In contrast to the self-expandable Corevalve, it
remains within the aortic sinus (f). Within both THVs, the pericardial
leaflets can be appreciated as fine hypodense linear structures
(arrowheads in c, f), its visibility dependent on image quality. Small
interposing calcifications (arrows in b, e) have in these examples only a
minimal effect on THV expansion. Reused from reference [40], with
permission
Table 2 Physical properties of
most commonly used THVand
sizing range (chapter 6)
SAPIEN 3 Evolut PRO/R
Manufacturer Edwards Lifesciences Medtronic
Available sizes (mm) 20 23
23 26
26 29
29 34
Annular range TEE (mm) 16–28 17/18–30 (17 for valve-in-valve only)
Deployment Balloon-expandable Self-expandable
Frame Cobalt-chromium Nitinol
Frame height (mm) 18–22.5 45 (46 mm for 34-mm valve)
Pericardial leaflets Bovine Porcine
Valve function Intra-annular Supra-annular
Repositionable No Yes
Ascending aorta fixation No No
Access routes Transfemoral Transfemoral
Transapical Transaxillary
Transaortic Transaortic
Transfemoral delivery sheath size 14F (16F for 29 mm valve) 16F
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Table 3 Overview of new generation TAVI devices
Device Manufacturer Material Deployment Valve 
locaon
Access 
Route
Evolut Pro/R
Medtronic
Porcine 
Ninol
Self-
Expandable
Supra-
annular
Retrograde
Sapien 3
Edwards 
Lifesciences Bovine 
Ninol
Balloon-
Expandable
Intra-
annular
Anterograde
Retrograde
Lotus
Boston 
Scienﬁc Bovine 
Ninol
Mechanical 
expansion
Intra-
annular
Retrograde
Porco
St. Jude 
Medical
Bovine 
Ninol
Self-
Expandable
Intra-
annular
Retrograde
Jena 
Valve
Jena-Valve
Technology Porcine 
Aorc 
root 
Ninol
Self-
Expandable
Intra-
annular
Anterograde
Retrograde
&
&
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root and one for the vascular access) during the same
session are preferable.
& Tailoring CT acquisition protocols to lower the required
volume of contrast material prevails over radiation dose
reduction given the fragile nature of the patient population
and the need for high quality images, with the newer CT
systems having the possibility to use one contrast bolus for
evaluation of access route and valve area.
& MR can be used as an alternative to CT for TAVI planning
but is more complex and may be considered in patients
with severely depressed renal function given the availabil-
ity of unenhanced MRI protocols.
CT
General scanner and acquisition requirements
CT scanning protocols should be optimised according to the
available technology, considering that two separate subse-
quent acquisitions are often necessary to cover a large ana-
tomic range from the subclavian to the femoral arteries, as
well as an ECG-gated acquisition of the aortic root.
Images should be reconstructed at 1.0 mm or less to enable
accurate multiplanar reformations. Therefore at least a 64-slice
or Dual-Source scanner is required.
Although radiation dose reduction is always an issue, in the
fragile patient population assessed for TAVI, reduction of io-
dinated contrast dose and avoiding the need for repeated con-
trast injection due to insufficient image quality is far more
important and should prevail over radiation dose reduction.
Potential intrinsic renal frailty of these patients is, in fact,
worsened by the need to use an additional contrast dose to
perform fluoroscopy and angiography following CTexamina-
tion, which may lead to higher risks of contrast-induced ne-
phropathy (CIN) and acute renal failure [32].
An ESCR recommended scanning protocol has been
summarised in a separate section of this article (Appendix 1)
for different commercially available single – and dual-source
CT scanners with normal and high-pitch protocols.
CTA of the aortic root
A retrospectively ECG-gated or prospectively ECG-triggered
CTA of at least the aortic root is mandatory for the motion-free
evaluation of the left ventricular outflow tract (LVOT), annu-
lus, sinus of Valsalva, sinotubular junction, ascending aorta
and coronary ostia. The annulus undergoes conformational
changes during the cardiac cycle; images are preferably ob-
tained at least during systole [33]. For prospectively ECG-
triggered scanning, the use of ECG-padding or a wide pulsing
window is recommended so multiple phases can be
reconstructed, increasing the likelihood of having at least
one motion-free phase in case of arrhythmia. A narrow field
of view centred on the aortic root should be used to increase
spatial resolution. In practice, an acquisition protocol used for
coronary imaging is usually a good starting point, requiring
only further modification to include high-quality systolic im-
ages (e.g. adaptation of dose modulation).
Optionally, a non-contrast-enhanced acquisition of the aor-
tic root is included, using acquisition parameters identical to a
non-contrast CT for coronary calcium scoring (120 KV, 3-mm
slices). This allows to calculate the calcium score of the aortic
valve.
CTA of the aorta and iliac arteries
Scan range should at least extend from the subclavian arteries
to the superficial femoral arteries at the level of the femoral
head. Depending on the scanner hardware, this may be the
same ECG-gated or ECG-triggered acquisition as for the aor-
tic root. This approach, however, frequently results in a rela-
tively high radiation and/or contrast dose compared with non-
gated acquisitions. Since a non-gated acquisition is adequate
to evaluate the aorto-femoral vessels, usually a second acqui-
sition following that of the aortic root is used. For modern
dual-source scanners, a single high-pitch acquisition triggered
at imaging the heart during systole may be used but offers only
one reconstruction phase of the annulus. This may be prob-
lematic in case of motion artefacts, with limited options to
improve image quality afterwards. Despite not constituting a
real late-phase acquisition, two subsequent acquisitions also
help to differentiate circulatory stasis in a large left atrial ap-
pendage from a real thrombus.
Contrast administration/volume
Fast anatomic coverage and low KV (70–80 kV), imaging is
especially recommended in this fragile patient group to allow
for a reduction in the amount of contrast agent [34]. A single
injection of contrast agent for both acquisitions is recommend-
ed. Around 50-ml contrast material in total at a flow rate of 3–
4 ml/s is often sufficient but should be adapted to the capabil-
ities of the CTsystem and the body habitus of the patient [34].
Medication
Nitroglycerine and beta-blockers are contraindicated in severe
aortic stenosis and should not be administered prior to
scanning.
MRI protocol
MRhas many potential advantages in TAVI planning [35, 36].
It quantitatively and radiation-free assesses aortic valve
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stenosis and regurgitation, coupled with accurate evaluation of
the impact of valvular disease on ventricular function. MR can
also provide all the measurements needed for the procedure,
comparable to cardiac CT. Evaluation of aorta and iliaco-
femoral arteries is also possible.
Additional strengths of MR imaging include the late en-
hancement evaluation of macroscopic fibrosis in aortic steno-
sis, the use of a gadolinium-based contrast medium which is
significantly less nephrotoxic and produces less adverse reac-
tions than its iodine-based CT counterpart and the ability to
perform a non-contrast-enhanced study in patients with se-
verely impaired renal function.
Nevertheless, its use is far less widespread for annular mea-
surements compared with CT. Probable reasons include a
technically more complex examination, a longer study time
and a higher required degree of patient cooperation. Also,
valve calcifications, while visible, are rendered with less de-
tail, and no calcium quantification is possible should this be
required. However, on a case-by-case basis, it may be consid-
ered over CT in patients with severely depressed renal
function.
A simplified MR protocol should start with coronal and
axial black blood ECG-gated half-Fourier fast spin echo im-
ages, acquired at end-expiration, for general chest evaluation.
Then steady state free precession (SSFP) cine images are
acquired at end-expiration along 2-chamber, 3-chamber and
4-chamber long axis and short axis. Furthermore, two long
axis cine images of the aortic root are obtained, the first in
an oblique coronal plane and the second obtained from the
first, along the plane passing through aortic root and ascend-
ing aorta. Finally, a stack of cine images are acquired orthog-
onally to the above two planes, covering the entire aortic root.
After these planes, mandatory for all the aortic and func-
tional measurements, a different approach can be used, based
on the patients’ renal function: if a contrast agent can be ad-
ministered, a multi-step contrast-enhanced MR angiography
(CE-MRA) is obtained, from aortic arch to proximal femoral
arteries. This represents the fastest approach, as the scan time
is less than 1 min, according to different sequences and accel-
eration factors.
In the presence of aortic valve stenosis or concurrent myo-
cardial diseases, a late enhancement sequence of the left ven-
tricle can be acquired, to assess macroscopic fibrosis.
In case of severe renal failure or known allergy to gadolin-
ium chelates, thoracic and abdominal aorta and iliaco-femoral
arteries can be assessed by means of different sequences: a 3D-
SSFP navigator-echo and ECG-gated (so-called whole heart)
sequence can be used for the thoracic aorta, while a non-
contrast-enhanced MRA (flow-enhanced based or flow-
independent based) can be used for aorto-iliac evaluation
[37]. Alternatively, the use of an intravascular contrast
(ferumoxytol) has been described, but is currently not widely
available in Europe [38].
An ESCR MR recommended protocol for pre-TAVI eval-
uation is given in Appendix 2.
Required CT-derived measurements
and imaging features before the procedure:
recommended stepwise approach
Consensus statement
& The main elements of CT in annular sizing are:
– to define a cross-sectional double-oblique image orienta-
tion in the correct plane of the aortic annulus
– to obtain accurate and standardised measurements of
different annular dimensions and height of coronary ostia
– to implement these measurements in the selection process
of a TAVI candidate in order to have the optimal
prosthesis-patient matching
& ECG-gated acquisitions are mandatory, with a preference
for systolic measurements.
& Evaluation of all potential access routes for suitability is
mandatory.
& For valve-in-valve procedures, simulated TAVI insertion is
mandatory to assess potential coronary obstruction.
Since direct measurements of the aortic root are not possi-
ble, imaging-based anatomic assessment forms an essential
pre-procedural step, crucial not only to determine TAVI eligi-
bility but also to select the optimal choice of device type and
size and the best pathway for device delivery.
The general principle of pre-TAVI CT imaging is to provide
motion-free high quality images of the aortic valvular com-
plex and root (i.e. aortic valve annulus, commissures, sinuses
of Valsalva [SOV], ostia of coronary arteries [OCA] and
sinotubular junction [STJ]) combined with a large longitudi-
nal coverage encompassing the entire aortic course between
the proximal supra-aortic vessels and the ilio-femoral axes for
access evaluation [39, 40].
High-quality ECG-gated CT images of the aortic root are
mandatory, as measurements should be performed in the sys-
tolic phase as the annulus undergoes conformational changes
during the cardiac cycle and is usually largest in systole [33].
However, image quality prevails over cardiac phase selection
as, depending on patient- and technical-related factors, dia-
stolic images may be of better quality providing more reliable
measurements. ECG gating of non-cardiac anatomy is not
routinely recommended, as it does not provide additional ben-
efit. However, as CT technology evolves, newer vendor-
specific CT protocols may be adapted by the local team in
order to achieve the best image quality possible.
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An overview of all required measurements is given in
Table 4.
Essential aortic root assessment
The aortic root extends from the left ventricular outflow tract
(LVOT) to the sinotubular junction and has a rather central
and double-oblique orientation in the heart (Fig. 2). As such, it
is ideally visualised using a 3D imaging modality. Standard
coronal, sagittal or even single-oblique image reformations
are therefore not considered suitable and lead to incorrect
measurements.
Assessment of the aortic root should include a description
of the aortic valve morphology, and measurement of different
annular dimensions at different cross-sectional levels of the
aortic sinus.
Aortic valve cuspidity
The aortic sinus contains the aortic valve, in most patients
composed of three distinctive aortic valve leaflets (Fig. 3). In
TAVI candidates, this valve is often significantly calcified.
The number of discernible valve leaflets or valve cuspidity
should always be commented on, although it may sometimes
be difficult to assess in heavily calcified valves (Fig. 4).
However, detection of a bicuspid valve is relevant because
AS is a known complication of a bicuspid aortic valve
(BAV), where valve remodelling and degeneration occur
faster and more often than in tricuspid valves. As such,
BAVs account for about half of all aortic valve replacements
for AS and are by extension therefore not rare in TAVI candi-
dates [41]. While a bicuspid valve morphology is not a con-
traindication for a TAVI procedure, it might increase proce-
dural complexity and is associated with a higher permanent
Table 4 Overview of required measurements
Anatomy Component Characteristics
Aortic valve
Cuspidity Bicuspid/tricuspid/undefinable
Valvular calcifications Amount (absent to severe)/location/distribution
Subvalvular calcifications Present or not, location, amount
Quantification of valve leaflet calcification Use the Agatston method, only indicated in discrepant
Doppler echocardiography results
Aortic annulus
short- and long-axis diameter (mm) Systolic measurements preferred, ensure correct
double-oblique annular plane orientationPerimeter (mm)
Area (mm2)
Aortic sinus
Height (mm) Requirements differ from type of THVand manufacturer
Width (mm)
Distance from annular plane to coronary ostia (mm)
Diameter sinotubular junction (mm)
Aorta
Maximum cross-sectional diameter of ascending aorta (mm)
Cross-sectional diameter at different levels (mm)
Wall characteristics Amount and distribution of calcification, thrombus,
ulcerative plaques, other findings
Access route
Diameter subclavian and common carotid arteries (mm) Minimal luminal diameters are required
diameter of brachiocephalic trunk (mm)
Diameter of common and external iliac arteries (mm)
Diameter of common femoral arteries
Wall characteristics Amount and distribution of calcification, thrombus,
ulcerative plaques, other findings
Left ventricular apex Myocardium characteristics, presence of thrombus,
other findings
Ascending aorta Wall characteristics, especially anterior and antero-lateral
wall for transaortic access
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pacemaker rate after implantation [42, 43]. Furthermore, BAV
presence in referred pre-TAVI candidates may also increase in
the future, as new studies and guidelines provide further sup-
port for potentially expanding TAVI indications to patients
with intermediate surgical risk and of potentially younger
age, in which BAV is thought to be more common [7, 44].
Amount, location and distribution of valvular calcifications
Due to mechanic effects, excessive or eccentric “landing
zone” calcifications may hamper appropriate prosthesis an-
chorage, leading to gaps between the prosthetic valve and
aortic annulus (Fig. 5). This may lead to the possible occur-
rence of paravalvular leak, which however cannot be further
assessed using CT [45]. Similarly, severe aortic valve calcifi-
cation is a known risk for annular rupture with balloon expan-
sion, prosthesis dislodgement (Fig. 6), coronary ostia obstruc-
tion (Fig. 7), calcific embolism and stroke [45, 46].
Besides quantitative assessments for diagnosis of AS,
which can be performed with CT using calcium-scoring tech-
niques in selected cases, we recommended to categorise cal-
cifications as symmetric or asymmetric and to visually score
the amount of valvular calcium depositions (mild, moderate or
severe), hereby considering the number and position of affect-
ed cusps (leaflet edges, commissures, and attachment sites)
(Fig. 8) and the distribution pattern (diffuse vs. focal,
subvalvular) (Fig. 9). A proposed classification for pre-TAVI
valvular calcifications visual grading is reported in Table 5.
Planimetry of the annular plane (see movies 2–4)
In contrast to previous beliefs, the aortic annulus is not a real
anatomic structure. It is better thought of as a descriptive term
commonly used by surgeons to indicate the virtual aortic wall
ring formed by connecting the nadirs of the attachment sites of
the aortic valve leaflets (at the basal portion of the sinus of
Valsalva) (Fig. 10). As such, it contains no fibrotic tissue. The
annular plane of the aortic annulus is therefore defined by
connecting these three lowest insertion points of the aortic
valve leaflets.
The aortic valve has a complex semilunar, crown-shaped
three-dimensional morphology, extending from the sinotubular
junction to the basal attachment plane of the aortic valve leaf-
lets (the so-called annular plane), located just below the
ventriculo-arterial junction (Fig. 11). Note that the lowest in-
sertion of the right coronary cusp leaflet is often inferior to the
left and non-coronary cusp leaflets.
The virtual ring addressed as aortic annulus was tradition-
ally assumed to be always circular. However, while on cross-
sectional imaging the aortic root contour is indeed practically
circular at the level of the STJ, it assumes a more clover-leaf
Fig. 3 The aortic sinus contains the aortic valve, in most patients
composed of three leaflets (asterisk in a, coloured dotted lines in b, c).
They are named according to the adjacent sinus of Valsalva (a): right
coronary sinus (red), left coronary sinus (green) and non-coronary sinus
(blue). As such, we distinguish (b, c) a right coronary cusp (red), left
coronary cusp (green) and non-coronary cusp (blue). The dotted dark
blue line in (c) indicates the sinotubular junction, marking the roof of
the aortic sinus
Fig. 2 3D volume rendering CT image of the heart containing the aortic
root. The aortic root has a double-oblique orientation within the heart.
Therefore, standard orthogonal imaging planes, like the axial plane
indicated with the dotted white line, are not suitable to correctly
visualise the aortic root and containing structures. For this reason,
intrinsic 3D imaging modalities like CT are necessary to correctly
assess the aortic root and annulus and obtain accurate measurements
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shape at the level of the aortic sinus, often becoming oval to
ellipsoid at the annular plane and the LVOT (Fig. 11). In heavi-
ly calcified anatomy with severe aortic stenosis/insufficiency,
the cross-sectional shape can be even more complex, difficult
to define and not comparable to geometric assumptions.
Exact measurements are crucial for a successful TAVI
procedure, as small differences in the choice of a measure-
ment plane in the aortic root and choice of start- and end-
point of the selected diameter can produce notably differ-
ent results, influencing the choice of THV size. Therefore,
high-quality images are essential in order to provide reli-
able measurements.
The main elements of CT in annular sizing are:
& Obtaining a cross-sectional image orientation in the cor-
rect plane of the aortic annulus
& Correctly and standardised measuring the annulus using
different methods
& Implementing these measurements in the selection process
of a patient-specific THV size.
A recommended stepwise approach to get a proper anatom-
ic orientation of the tricuspid aortic annulus is displayed in
Fig. 12 (see movies 2–3). Currently, there is no consensus
on how to define the annular plane in bicuspid aortic valves
as the basal attachments of the two leaflets provide only two
landmarks out of a necessary three to define a plane in space.
Once a suitable plane has been obtained, several annular
measurements can be taken. We propose the calculation of the
mean annular diameter using the three following methods, as
stated preferentially based on systolic images as they provide
the largest possible annular dimensions (Fig. 13).
Fig. 5 Incomplete and asymmetric deployment of a self-expandable
THV due to interposition of extensive native leaflet calcifications
(arrow in a, b) between the prosthetic valve and the wall of the aortic
sinus. Severe calcifications can complicate prosthesis deployment as in
this case, leading to a deformed THV. Nevertheless, caution should be
taken when extrapolating morphological findings into a potential
dysfunction. While in this case the residual gap between the THV and
the aortic wall would suggest a severe paravalvular leakage, this was not
the case onDoppler echocardiography examination, with the calcification
apparently acting as an additional seal. Valvular function was acceptable,
and no further intervention was deemed necessary
Fig. 4 Most TAVI candidates will present with an aortic valve containing
significantly calcified valve leaflets. The majority of patients will have a
clearly identifiable tricuspid aortic valve (a). However, a significant
portion will have a bicuspid aortic valve, which is an important feature
to report as its presence is associated with some specific complications.
However, in some cases, valve cuspidity can be difficult to assess in
heavily degenerated valves, where extensive calcification can make
differentiation between tricuspid and (functionally) bicuspid valves
difficult (b)
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First, we obtain annular cross-sectional long- (DL) and
short-axis (DS) diameters.
Then, the annular perimeter is manually tracked using a
planimetry tool on a workstation, after which area A and cir-
cumference C of the aortic annulus are derived by the work-
station software. Finally, the mean annular diameter D is cal-
culated based on these different measurements. For the cross-
sectional-derived mean diameter DCS, this is done by simple
averaging (DCS = (DL + DS)/2). The area (DA) and
circumference-derived (DC) effective diameter are calculated
as follows: DA = 2 × √(A / π ), and DC = C/ π.
It is however important to realise that DC and DA are
calculated under the assumption of full circularity of the
annulus after device deployment, a feature almost exclusively
found in deployed balloon-expandable valves. The discrepan-
cy between these three measurements (DCS, DA and DC) will
therefore increase with remaining annular eccentricity, most
notably in the circumference-based method. This further un-
derlines the important concept that transcatheter valve size
selection is closely tied to the type of device used and that
sizing algorithms are not strictly interchangeable.
When borderline results not allow to choose between two
different potential prosthesis sizes (e.g. 23 vs. 26 mm), it is
recommended to do a blinded complete re-measurement in
order to acquire more certainty, together with all available
imaging data from different sources.
Additional recommended measurements in the aortic
root
Minimum distance of the annulus to the left and right ostium
of the coronary arteries (see movies 5–6)
Coronary obstruction secondary to migrated calcified and
non-calcified native valve components during device deploy-
ment is a rare procedural complication with a reported inci-
dence of 0.8%, increasing to 3.5% in valve-in-valve proce-
dures [47, 48]. It usually occurs during the procedure but
has been reported up to 24 h after device deployment [49,
50]. Patients with a more susceptible anatomy for this compli-
cation have a combination of a low-lying ostia of the coronary
arteries (OCA) with a large native aortic valve leaflet.
Distance should be measured by tracing a perpendicular
line connecting the inferior edge of OCA with the aortic an-
nulus plane, as the risk of obstruction is considered to be low if
this height is more than 10–14 mm [39, 51]. Minimum dis-
tance to OCA should also obviously be calculated in relation
to the length of the aortic valve cusps. A recommended
Fig. 7 Relation between the coronary ostia and the deployed THV. Both
self-expandable and balloon-expandable THVs are designed not to
obstruct the coronary ostia, with self-expandable Corevalve and Evolut
protheses extending into the ascending aorta by design, leaving the
coronary ostia open (a, b). When coronary obstruction occurs, it is not
by the THV but secondary to displaced calcified native leaflet remnants
that migrate during deployment of the THV in the aortic sinus to the
vicinity of the coronary ostia. Nevertheless, while CT can detect these
migrated calcifications in or near the coronary ostia (c), the evaluation of
luminal patency is less obvious, mostly dependent on local expertise and
the quality of the CT scanner used
Fig. 6 Incorrect positioned THV, which is tilted and does not fully extend
into the aortic annulus. As such, parts of the native right aortic valve leaflet
is protruding into the inflow part of this self-expandable THV (arrow),
causing a residual valve gradient on Doppler echocardiography. CT is
very useful in detecting the cause of THV dysfunction in cases where
Doppler echocardiography does not provide an answer. In this case,
function was improved after balloon dilatation of the inflow part of the
THV, further crushing the remaining valve leaflets against the adjacent
aortic wall
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stepwise approach to measure the minimum distance of the
OCA is displayed in Fig. 14.
Largest dimensions of the aortic sinus and sinotubular
junction (see movies 7–8)
The largest diameter of the aortic sinus diameter and height
should be assessed on a double-oblique projection. The sinus
of Valsalva acts as a reservoir for the displaced native aortic
valve calcifications after device deployment. The necessary
dimensions of the aortic sinus are specified by the manufac-
turer of the specific device that will be implanted and varies
from model to model.
Determination of optimal c-arm angulation
There is a remarkable individual variation of anatomic posi-
tion of the aortic valve, which is usually projecting with a
slight degree of caudal angulation in the right anterior oblique
(RAO) projection and cranial angulation when in the left an-
terior oblique (LAO) [52]. During the procedure, the correct
tube projection has to be determined in order to define the
optimal fluoroscopic orientation consistent with an orthogonal
view of the aortic valve plane. More specifically, a view with
the origin of the right coronary artery pointing towards the
viewer and the inferior margins of the three coronary cusps
projecting at equal size and distance to each other with the
right coronary cusp in the middle, the left coronary cusp to the
left and the non-coronary cusp to the right. Without 3D imag-
ing guidance, this would require multiple aortograms,
Fig. 8 CT images of the aortic
valve illustrating different degrees
of valvular calcification
depositions: none (a), mild (b),
moderate (c) and severe (d). Also
note the differences in the affected
cusps and distribution (leaflet
edges, commissures and
attachment sites)
Fig. 9 Double-oblique CT image of the aortic root in a TAVI candidate.
While most calcification will be on a supra-annular level (arrowhead),
occasionally, calcifications can also be found on an infra-annular
subvalvular level (arrow). Reporting of these latter calcifications is
important, as they can hamper proper deployment and attachment of the
prothesis
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increasing not only procedural time but also contrast volume,
potential contrast-induced nephrotoxicity and radiation dose.
However, imaging-based prediction of the correct aortic
annulus angle projection can reliably be derived from pre-
procedural CT data, increasing procedural efficacy [53].
Therefore, we recommend providing this information in every
report.
Nevertheless, a major limitation of CT-based prediction
of aortic annulus projection is the assumption that a pa-
tient’s position would be comparable between the CT ac-
quisition and the actual procedure, which is not always the
case.
Measurements for valve-in-valve procedures
For the valve-in-valve procedures, the size of the in situ sur-
gical aortic valve prosthesis determines the maximum TAVI
size that can be implanted. Often this is known from the sur-
gical report. If they are not known, the type and size can be
deducted from the CT appearance and standardised measure-
ments [54, 55]. The main concern with valve-in-valve proce-
dures is obstruction of the coronary artery ostium by the leaf-
lets or struts of the surgical aortic valve and is much more
common than in regular TAVI.
To simulate the effect of TAVI implantation on the coro-
nary arteries, a circular region of interest/cylinder with the
same diameter of the TAVI valve to be implanted is drawn at
the level of the coronary artery ostium [54]. In this simulated
TAVI implantation, the distance of the coronary ostium to the
virtually implanted device can be measured. The thresholds
for a safe minimal distance have not yet been defined or val-
idated in large cohorts but several millimetres are considered
to be necessary at least.
Evaluation of the access route
Before actual THV deployment, the prosthetic heart valve has
to be transported to the aortic root using a non-surgical ap-
proach. Several options are currently available.
Arterial transfemoral access remains the approach of pref-
erence for all devices. Alternative entry points through the
subclavian, common carotid and brachiocephalic artery are
also possible for both BE and SE THV. SAPIEN devices ad-
ditionally allow a left ventricular transapical approach.
Finally, many centres have increasing experience using a min-
imally invasive transaortic pathway using a mini-sternotomy,
applicable to both types of valves. The entrance point for
transaortic access is about 6 cm above the annular plane
(Fig. 15). All except the transfemoral approach require a sur-
gical incision for initial access.
Regarding access sites, THVs come with a custom-
made and device-specific delivery system for the transpor-
tation of the prosthetic valve. Different sheath sizes exist
depending on the manufacturer and the production version
of the device. Ideally, the minimal native vessel size
should be larger than the outer diameter of the chosen
delivery sheath. As such, smaller profile sheaths and de-
livery catheters improve procedural safety and expand pa-
tient eligibility. Currently, both Medtronic and Edward
Lifesciences have 14F sheaths (16F for 29 mm Sapien 3
valve and 34 mm Evolut R valve) for transfemoral deliv-
ery. Depending on the chosen delivery system and THV
size, the minimal vessel diameter can be as low as
5.5 mm. Delivery catheters are nevertheless the subject
of intense research and have been continuously improved
ever since their introduction, with other systems currently
being developed by different vendors.
As can be expected, a larger sheath size (22–24F) has been
associated with a higher incidence of vascular complications
varying from 23 to 31% compared with smaller systems (1.9–
13.3%). Known risk factors which should be looked for in-
clude (Fig. 16):
Fig. 10 3D CT image of the aortic root containing the sinuses of Valsalva
(asterisk). As the aortic valve leaflets extendwithin these sinuses up to the
sinotubular junction, connecting their most basal attachment sites forms a
virtual ring which is named the aortic annulus (red dotted line, arrows). It
also marks the transition to the LVOT
Table 5 Visual description and grading of aortic valve calcifications
Semi-quantitative pre-TAVI grading of valvular calcifications
Absent No calcifications
Mild Small isolated focal spots not involving commissures and
attachments sites
Moderate Large confluent calcifications affecting 2 cusps or Small
isolated focal spots at the level of all commissures and
attachments sites
Severe Large confluent calcifications affecting all cusps
Large tables, see separate document
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& Amount and distribution of atherosclerotic (specifically
circumferential) wall thrombi and calcifications
& Small native vessel size (below the outer diameter of the
used delivery sheath)
& Prominent tortuosity of the iliac arteries and aorta.
Endovascular approach
Practically, the minimal luminal (excluding vessel wall) diam-
eter of the access vessels on both sides (common femoral
artery, external iliac artery and common iliac artery as well
Fig. 11 a Schematic drawing illustrating the crownlike suspension of the
aortic valve leaflets within the aortic root extending across the length of
the aortic sinus (a). AR, virtual annular ring representing the annulus
(green), formed by joining the basal attachments of the aortic valve
leaflets; STJ, sinotubular junction (blue); VAJ, ventriculo-arterial
junction (yellow). Red, aortic leaflet insertion sites in the sinus of
Valsalva forming a crownlike ring. b Coronal contrast-enhanced CT
image demonstrates the levels of the sinotubular junction (STJ) (blue
line), ventriculo-arterial junction (VAJ) (yellow line) and annular ring
(AR) (green line). Double-headed arrow, anatomic range of the sinuses
of Valsalva. CAU, caudal; CRA, cranial. c–f Double-oblique reformatted
images further clarify the changing shape of the aortic root contour. c The
sinotubular junction forms the top of the crown, where the outlet of the
aortic root in the ascending aorta (Ao) is a true circle. A, anterior; P,
posterior; L, left; R, right. d The aortic root gradually becomes less
circular, with a more cloverleaf shape at its midportion (i.e. at the
sinuses of Valsalva). At this level, the aortic valve leaflets are clearly
seen. e The aortic valve leaflets (asterisk) are just barely visible at the
level of the ventriculo-arterial junction, where the left ventricular
structures give rise to the fibroelastic walls of the aortic valvar sinuses.
Note that the aortic root contour is now becoming increasingly ellipsoid. f
The bottom of the aortic root is formed by the virtual ring, or aortic
annulus (Aoann), which has an oval shape in most patients. Reused
from reference [39], with permission
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Fig. 12 For all measurements of the aortic root as illustrated in Figs. 12,
13 and 14, the use of a (simple) multiplanar reconstruction viewer is
mandatory. The three imaging planes should be perpendicular to each
other at 90° angles and the reference lines should be “locked” so
rotating one reference line automatically rotates the other planes. Care
should be taken to have the screen layout setting in such a way that all
three imaging planes (starting with axial, coronal and sagittal) are visible
simultaneously. The CTA dataset (preferably a systolic phase) is loaded
into the viewer. a First, in the coronal plane the aortic valve is located and
the centre of the reference lines is placed approximately at the centre of
the aortic valve. In the coronal image plane, the references lines are
rotated so one of the two lines is at approximately 45° to the horizontal
level. This results in the images seen in b. In the plane that was the
original sagittal reconstruction (middle panel in b), the reference line is
also rotated to be approximately parallel to the aortic valve. This generally
provides a pretty good imaging plane that is perpendicular to the aortic
valve (right panel in b). The essential step (illustrated in c) is to scroll up
and down through this image stack (as indicated by the straight arrows in
the other views in c) and determine if all three aortic valve cusps are seen
symmetrically in each image (i.e. scrolling from the level of the LVOT to
the aortic valve, the three cusps should appear symmetrically and
simultaneously in one image). This is often not yet the case. By
tweaking the angulation of the plane by slight rotation of the crosshairs
in the other views (as indicated by the curved arrows in c) while assessing
its effect on the symmetry of the valve leaflets in the in-plane image is
needed to have the cusps appear symmetrically. Once this has been
established, by scrolling through the image stack in-plane with the
aortic valve towards the LVOT, the leaflets will increasingly appear
smaller and closer to the aortic wall (d, see arrowheads in right panel).
The first image just below the level of the lowest image (i.e. closest to the
LVOT) that no longer shows the leaflets is selected and represents the
annulus (e)
Eur Radiol
as abdominal and thoracic aorta) should be determined using
double-oblique reformations to obtain the correct cross-
sectional diameter perpendicular to the longitudinal vessel
axis.
Selection of anatomic access point should be based on the
concept of selecting the least invasive possible route for TAVI.
As previously stated, transfemoral approach should always be
the first option, with an alternative approach to be only
Fig. 14 Standardised way to
perform measurements of the
distance of the annular plane to
the ostium of the right coronary
artery and left main. The starting
points are the annular plane
images (obtained through the
steps outlined in Fig. 12) as
displayed in a–c above. In this
image stack, in plane with the
annulus, the origin of the RCA is
located by scrolling through the
images in the direction of the
aorta (arrows in a, b).
Subsequently, the reference lines
are rotated (curved arrow in c) in
such a way that one of the
reference lines passes through the
RCA ostium (asterisk in f); then,
by scrolling toward the LVOT
(arrows in d, e), the annulus plane
is again displayed (i) and in one of
the two other panels (h), the
origin of the RCA is visible
(asterisk in h), as well as the
reference line which corresponds
to the annulus plane level (red line
in h). The distance is measured as
the distance of the lower border of
the RCA ostium (asterisk in j, k)
to the attachment of the coronary
cusp (j) or perpendicular to the
reference line of the annulus plane
(k). For the distance of the
annulus to the left main, the steps
mentioned above are repeated
Fig. 13 The annular plane image obtained through the steps outlined in
Fig. 12 is used for the measurements. The long- and short-axis diameters
are measured using a simple distance tool (a). In the annular plane, the
circumference of the annulus is traced using a planimetry tool (b). Most
software systems then automatically display the area, perimeter and area-
derived diameter of the traced area (c). Alternatively, parameters can be
calculated as described in the text
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selected in the setting of a prohibitively luminal compromise
due to the mentioned risk factors.
At present, specific cut-offs for the definition of tortuosity
degree or extent of calcifications have not been established.
Non-endovascular approach
Any potential obstruction or complication along the cho-
sen access route should be reported. For LV transapical
access, no abnormalities should be present in the regional
thoracic wall or in the apical myocardium (e.g. apical
infract with apical thrombus). Also, the angulation be-
tween the LV apex and the LVOT must be documented,
as steeper angles may complicate the procedure with rigid
delivery systems, and is associated with a higher inci-
dence of post-procedural PAR [56, 57].
If a transaortic approach is considered, the amount and
location of wall calcification in the ascending aorta should
be documented, as extensive anterior aortic wall calcifica-
tion may compromise device passage and increase the risk
of complications. Furthermore, any abnormalities in the
adjacent lung parenchyma and thoracic wall should be
described.
Recommended standardised medical report
in pre-TAVI assessment
Consensus statement
& The report of a pre-TAVI assessment CT or MRI should
include all relevant information and measurements of the
aortic root and access routes.
& Structured reports are highly recommended to ensure all
relevant information is included and facilitate communi-
cation of results.
Fig. 15 The target point (T) in case of a transaortic THV delivery. When
the usual endovascular or transapical delivery routes are not possible, the
transaortic pathway offers an alternative for patients in which no other
access is possible. The recommended entry point for self-expandable
THV is located at least 6 cm above the level of the aortic annulus
(annular plane in red dotted line). Furthermore, the status of the aortic
wall around this location needs to be scrutinised, as e.g. extensive
calcification increases procedural feasibility and risk, and may as such
make this access path unsuitable. However, even for transaortic access
caution is needed. The TAVI candidate might have previous coronary
bypass grafts, including a venous bypass over the RCA (arrow in c).
The origin of this bypass (asterisk in c) might be near the targeted entry
point, in this case about 6 cm above an annular plane with a heavily
calcified aortic valve (arrowhead in c). Also, the anterior wall of the
ascending aorta may show extensive calcification (arrow in d), making
transaortic access impossible. Note incidental visualisation of an
extensive calcified RCA (asterisk in d)
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For the analysis of pre-TAVI assessment examinations,
structured reports are highly recommended to ensure that all
necessary information to TAVI is provided by the report and to
assist in consistent communication of data between various
sites and specialists involved in the procedural planning.
Furthermore, a standardised structure allows for fast and
easy recognition of the relevant findings for the clinician
performing the TAVI procedure. Finally, it is a useful educa-
tive tool for residents and CT technicians. As a proposal, a
template for structural reporting is available on the ESCR
website (www.escr.org), accessible for ESCR members only.
In the following, the requested parameters that have to be
addressed in a pre-TAVI report are listed and explained.
Since the usual patients evaluated for a TAVI procedure are
aged, renal impairment is frequent. Thus, low contrast volumes
should be used, which is possible in TAVI evaluation without the
risk of insufficient arterial enhancement, since the severe aortic
stenosis, per definition present in TAVI patients, leads to reduced
cardiac output. The iodine concentration and total contrast vol-
ume given should be provided in the standardised report.
The report prior to TAVI should contain measurements
and statements about three different anatomical levels: aor-
tic valve and aortic annulus, sinus of Valsalva and access
vessels.
For the description of the aortic valve and aortic annulus, a
qualitative description of aortic valve calcification should be
provided in similarity to the grading that was introduced for
echocardiography. Thus, aortic valve calcification should be
described as none, mild, moderate and severe. Additionally,
asymmetric extension of calcifications either to the aortic-
mitral curtain or to the membranous septum should be men-
tioned, as well as possible morphological abnormalities (for
example bicuspid valve). Furthermore, the diameter of the
aortic annulus should be measured. Addressing the asymmet-
ric shape of the annulus, a single diameter is not sufficient.
Thus, at least the maximal and the minimal diameters of the
aortic annulus at systole have to be reported. Alternatively,
and more accurately, the area could be measured. The pros-
thesis size can be inferred from those measurements and sug-
gested to the cardiology team.
Fig. 16 Compromised delivery paths. A safe endovascular trajectory is
needed for safe transportation of the THV to the aortic root. CT is in his
respect an essential tool in order to avoid vascular complications and
guide to the intervention through the safest possible passage. Potential
complications may arise due to luminal narrowing or even chronic iliac
artery occlusion with extensive collaterals (a) and pronounced vascular
tortuosity and kinking (arrows in b). In this last case, there is an additional
short dissection in the left external iliac artery (arrowhead) due to a
previously performed conventional coronary angiography. For these
patients, the preferred transfemoral access approach is therefore not
possible, and other options have to be considered. Nevertheless, other
access paths may also pose significant challenges, like bilateral
subclavian artery narrowing and occlusion (arrows in c), and the
presence of post-infarct thrombus and wall calcification in the left
ventricular apex (asterisk in d), making a transapical approach with a
balloon-expandable valve impossible. Therefore, vascular access
examination must include all anatomic possible entry points for a full
assessment of the different options
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The second anatomical target region to be assessed is
the sinus of Valsalva. Severely calcified atheromas at
the level of the sinus and the ascending aorta have to
be described. Although still in most centres invasive
coronary angiography is performed in all patients prior
to TAVI, coronary arteries should be described in the
CT report as well. This information includes the pres-
ence or absence of coronary anomalies or anatomical
variants of coronary anatomy, as well as the presence
or absence of coronary calcifications. To avoid any
compromise of coronary ostia by aortic leaflets, the
minimal distance between the aortic annulus and the
coronary orifices has to be measured and reported.
Also, the three diameters—referring to the three parts
of the sinus—should be assessed. Additionally, the
height of the sinus of Valsalva and the aortic diameter
at the level of the STJ and at 40 mm distally to the
aortic annulus are important measurements for appropri-
ate planning prior to a TAVI.
The third crucial part of any CT report prior to TAVI
consists in the description of the access vessels. The
main parameters include vessel tortuosity, vessel wall
calcifications and minimal diameter along the access
route. Severe thrombotic and/or atherosclerotic wall
changes within the entire aorta have to be reported. To
avoid any confusion, it is recommended to describe the
important findings for each side separately and to end
up with a recommendation of the preferred access route.
The severity of vessel tortuosity and calcification along
the iliaco-femoral axis should be graded for both sides
using a three-point qualitative grading score ranging
from low to moderate up to severe. Furthermore, the
minimal and mean diameters have to be measured at
the level of the puncture site (common femoral artery),
for the common femoral and external iliac, and for the
common iliac artery. Calcified plaques and the presence
and severity of stenosis should be documented for the
vascular territories described above as well.
A critical and difficult issue for CT assessment prior
to TAVI is the fact that a CTA of the entire aorta rep-
resents in fact a CT of the whole body. Thus, beside all
assessments and measurements as described above, care-
ful assessment of extra-arterial findings is needed—even
if it is time-consuming. Given the known comorbidities
and the age of the usual TAVI patients, the pre-test
probability for unexpected findings potentially important
for further patient care and outcome is relatively high.
Consequently, every relevant unexpected finding should
be reported even during pre-TAVI assessment since this
can also influence the treatment decision-making
process.
A proposed template for pre-TAVI standardised report is
provided in Appendix A.
Conclusions
Clinical decision-making for the selection of TAVI candidates is a
complex multifactorial process taking into account not only spe-
cific hemodynamic and anatomic features but also amore general
comprehension of the risk-benefit ratio of the procedure, with
regard for the patient’s intrinsic frailty and degree of disability [9].
Multimodality imaging plays an important role in this mul-
tidisciplinary decision-making, allowing accurate selection of
the appropriate valvular device and procedural access, to min-
imise complications rate and improve the patient’s outcome.
CT remains the preferable and most utilised tool in clinical
practice to obtain comprehensive pre-procedural information
from annular and aortic root size and morphology to coronary
arteries and peripheral vascular anatomy [9].
MR is an alternative modality in case CT is no option,
combining accurate morpho-functional assessment of aortic
valvular disease with prognostic information derived from
the assessment of tissue fibrosis; vascular anatomy can also
be assessed using unenhanced free breathing or navigator-
assisted techniques which allow to minimise renal exposure
to contrast media with impaired renal function [35, 37].
Regardless the method chosen for pre-procedural imaging,
rigorous standardisation of the scanning protocols, measure-
ments and medical reporting is critical to assure an adequate
image quality and consistency of reported data and terminol-
ogy between different centres and physicians.
Funding The authors state that this work has not received any funding.
Compliance with ethical standards
Guarantor The scientific guarantor of this publication is Prof. Marco
Francone.
Conflict of interest The authors of this manuscript declare no relation-
ships with any companies, whose products or services may be related to
the subject matter of the article.
Statistics and biometry No complex statistical methods were necessary
for this paper.
Informed consent Written informed consent was not required for this
study because it is structured in the form of a consensus article.
Ethical approval Institutional Review Board approval was not required
because it is structured in the form of a consensus article.
Methodology
• multicentre consensus
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
Eur Radiol
References
1. Bach DS, Siao D, Girard SE, Duvernoy C, McCallister BD Jr,
Gualano SK (2009) Evaluation of patients with severe symptomatic
aortic stenosis who do not undergo aortic valve replacement: the
potential role of subjectively overestimated operative risk. Circ
Cardiovasc Qual Outcomes 2:533–539
2. Iung B, Cachier A, Baron G et al (2005) Decision-making in elderly
patients with severe aortic stenosis: why are so many denied sur-
gery? Eur Heart J 26:2714–2720
3. Cribier A, Eltchaninoff H, Bash A et al (2002) Percutaneous trans-
catheter implantation of an aortic valve prosthesis for calcific aortic
stenosis: first human case description. Circulation 106:3006–3008
4. Hamm CW, Arsalan M, Mack MJ (2016) The future of transcath-
eter aortic valve implantation. Eur Heart J 37:803–810
5. Osnabrugge RL, Mylotte D, Head SJ et al (2013) Aortic stenosis in
the elderly: disease prevalence and number of candidates for trans-
catheter aortic valve replacement: a meta-analysis and modeling
study. J Am Coll Cardiol 62:1002–1012
6. Blanke P, Weir-McCall JR, Achenbach S et al (2019) Computed
tomography imaging in the context of transcatheter aortic valve
implantation (TAVI)/transcatheter aortic valve replacement
(TAVR): an expert consensus document of the Society of
Cardiovascular Computed Tomography. JACC Cardiovasc
Imaging 12:1–24
7. Baumgartner H, Falk V, Bax JJ et al (2017) 2017 ESC/EACTS
guidelines for the management of valvular heart disease. Eur
Heart J 38:2739–2791
8. Nishimura RA, Otto CM, Bonow RO et al (2014) 2014 AHA/ACC
guideline for the management of patients with valvular heart dis-
ease: executive summary: a report of the American College of
Cardiology/American Heart Association Task Force on Practice
Guidelines. Circulation 129:2440–2492
9. Otto CM, Kumbhani DJ, Alexander KP et al (2017) 2017 ACC
expert consensus decision pathway for transcatheter aortic valve
replacement in the management of adults with aortic stenosis: a
report of the American College of Cardiology Task Force on
Clinical Expert Consensus Documents. J Am Coll Cardiol 69:
1313–1346
10. Vahanian A, Alfieri O, Andreotti F et al (2012) Guidelines on the
management of valvular heart disease (version 2012): the Joint Task
Force on the management of valvular heart disease of the European
Society of Cardiology (ESC) and the European Association for
Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg 42:
S1–S44
11. Nashef SA, Roques F, Sharples LD et al (2012) EuroSCORE II. Eur
J Cardiothorac Surg 41:734–744 discussion 744-735
12. Svensson LG, Adams DH, BonowRO et al (2013) Aortic valve and
ascending aorta guidelines for management and quality measures:
executive summary. Ann Thorac Surg 95:1491–1505
13. Reardon MJ, Van Mieghem NM, Popma JJ et al (2017) Surgical or
transcatheter aortic-valve replacement in intermediate-risk patients.
N Engl J Med 376:1321–1331
14. Leon MB, Smith CR, Mack MJ et al (2016) Transcatheter or sur-
gical aortic-valve replacement in intermediate-risk patients. N Engl
J Med 374:1609–1620
15. Dvir D, Webb JG, Bleiziffer S et al (2014) Transcatheter aortic
valve implantation in failed bioprosthetic surgical valves. JAMA
312:162–170
16. Mylotte D, Lefevre T, Sondergaard L et al (2014) Transcatheter
aortic valve replacement in bicuspid aortic valve disease. J Am
Coll Cardiol 64:2330–2339
17. ClavelMA,Messika-Zeitoun D, Pibarot P et al (2013) The complex
nature of discordant severe calcified aortic valve disease grading:
new insights from combined Doppler echocardiographic and com-
puted tomographic study. J Am Coll Cardiol 62:2329–2338
18. Clavel MA, Pibarot P, Messika-Zeitoun D et al (2014) Impact of
aortic valve calcification, as measured by MDCT, on survival in
patients with aortic stenosis: results of an international registry
study. J Am Coll Cardiol 64:1202–1213
19. Baumgartner H Chair, Hung J Co-Chair, Bermejo J et al (2017)
Recommendations on the echocardiographic assessment of aortic
valve stenosis: a focused update from the European Association of
Cardiovascular Imaging and the American Society of
Echocardiography. Eur Heart J Cardiovasc Imaging 18:254–275
20. Aggarwal SR, Clavel MA, Messika-Zeitoun D et al (2013) Sex
differences in aortic valve calcification measured by multidetector
computed tomography in aortic stenosis. Circ Cardiovasc Imaging
6:40–47
21. Zamorano J, Goncalves A, Lancellotti P et al (2016) The use of
imaging in new transcatheter interventions: an EACVI review pa-
per. Eur Heart J Cardiovasc Imaging 17:835–835af
22. Klass O, Walker MJ, Olszewski ME et al (2011) Quantification of
aortic valve area at 256-slice computed tomography: comparison
with transesophageal echocardiography and cardiac catheterization
in subjects with high-grade aortic valve stenosis prior to percutane-
ous valve replacement. Eur J Radiol 80:151–157
23. Singh A, McCann GP (2019) Cardiac magnetic resonance imaging
for the assessment of aortic stenosis. Heart 105:489–497
24. Pulignano G, Gulizia MM, Baldasseroni S et al (2017) ANMCO/
SIC/SICI-GISE/SICCH executive summary of consensus docu-
ment on risk stratification in elderly patients with aortic stenosis
before surgery or transcatheter aortic valve replacement. Eur
Heart J Suppl 19:D354–D369
25. Goel SS, Bajaj N, Aggarwal B et al (2014) Prevalence and out-
comes of unoperated patients with severe symptomatic mitral re-
gurgitation and heart failure: comprehensive analysis to determine
the potential role of MitraClip for this unmet need. J Am Coll
Cardiol 63:185–186
26. Trenkwalder T, Lahmann AL, Nowicka M et al (2018) Incidental
findings in multislice computed tomography prior to transcatheter
aortic valve implantation: frequency, clinical relevance and out-
come. Int J Cardiovasc Imaging. https://doi.org/10.1007/s10554-
018-1305-5
27. Abramowitz Y, Maeno Y, Chakravarty T et al (2016) Aortic angu-
lation attenuates procedural success following self-expandable but
not balloon-expandable TAVR. JACC Cardiovasc Imaging 9:964–
972
28. Tchetche D, Van Mieghem NM (2014) New-generation TAVI de-
vices: description and specifications. EuroIntervention 10(Suppl
U):U90–U100
29. Pontone G, Andreini D, Bartorelli AL et al (2012) Aortic annulus
area assessment by multidetector computed tomography for
predicting paravalvular regurgitation in patients undergoing
balloon-expandable transcatheter aortic valve implantation: a com-
parison with transthoracic and transesophageal echocardiography.
Am Heart J 164:576–584
30. Wendler O, Schymik G, Treede H et al (2017) SOURCE 3 registry:
design and 30-day results of the European postapproval registry of
the latest generation of the SAPIEN 3 transcatheter heart valve.
Circulation 135:1123–1132
31. Wiegerinck EM, Van Kesteren F, VanMourikMS, Vis MM, Baan J
Jr (2016) An up-to-date overview of the most recent transcatheter
implantable aortic valve prostheses. Expert Rev Med Devices 13:
31–45
32. Scherner M, Wahlers T (2015) Acute kidney injury after transcath-
eter aortic valve implantation. J Thorac Dis 7:1527–1535
33. Sucha D, Tuncay V, Prakken NH et al (2015) Does the aortic an-
nulus undergo conformational change throughout the cardiac cycle?
Eur Radiol
A systematic review. Eur Heart J Cardiovasc Imaging 16:1307–
1317
34. KokM, Turek J, Mihl C et al (2016) Low contrast media volume in
pre-TAVI CT examinations. Eur Radiol 26:2426–2435
35. Chaturvedi A, Hobbs SK, Ling FS, Chaturvedi A, Knight P (2016)
MRI evaluation prior to transcatheter aortic valve implantation
(TAVI): when to acquire and how to interpret. Insights Imaging 7:
245–254
36. Mayr A, Klug G, Reinstadler SJ et al (2018) Is MRI equivalent to
CT in the guidance of TAVR? A pilot study. Eur Radiol. https://doi.
org/10.1007/s00330-018-5386-2
37. Ruile P, Blanke P, Krauss T et al (2016) Pre-procedural assessment
of aortic annulus dimensions for transcatheter aortic valve replace-
ment: comparison of a non-contrast 3D MRA protocol with
contrast-enhanced cardiac dual-source CT angiography. Eur Heart
J Cardiovasc Imaging 17:458–466
38. Nguyen KL, Moriarty JM, Plotnik AN et al (2018) Ferumoxytol-
enhanced MR angiography for vascular access mapping before
transcatheter aortic valve replacement in patients with renal impair-
ment: a step toward patient-specific care. Radiology 286:326–337
39. Salgado RA, Leipsic JA, Shivalkar B et al (2014) Preprocedural CT
evaluation of transcatheter aortic valve replacement: what the radi-
ologist needs to know. Radiographics 34:1491–1514
40. Salgado RA, Budde RP, Leiner T et al (2014) Transcatheter aortic
valve replacement: postoperative CT findings of Sapien and
CoreValve transcatheter heart valves. Radiographics 34:1517–1536
41. Perlman GY, Blanke P, Webb JG (2016) Transcatheter aortic valve
implantation in bicuspid aortic valve stenosis. EuroIntervention 12:
Y42–Y45
42. Jilaihawi H, Chen M, Webb J et al (2016) A bicuspid aortic valve
imaging classification for the TAVR era. JACCCardiovasc Imaging
9:1145–1158
43. Wijesinghe N, Ye J, Rodes-Cabau J et al (2010) Transcatheter aortic
valve implantation in patients with bicuspid aortic valve stenosis.
JACC Cardiovasc Interv 3:1122–1125
44. Webb J, Gerosa G, Lefevre T et al (2014) Multicenter evaluation of
a next-generation balloon-expandable transcatheter aortic valve. J
Am Coll Cardiol 64:2235–2243
45. Haensig M, Rastan AJ (2012) Aortic valve calcium load before
TAVI: is it important? Ann Cardiothorac Surg 1:160–164
46. Fassa AA, Himbert D, Vahanian A (2013) Mechanisms and man-
agement of TAVR-related complications. Nat Rev Cardiol 10:685–
695
47. Dvir D, Webb J, Brecker S et al (2012) Transcatheter aortic valve
replacement for degenerative bioprosthetic surgical valves: results
from the global valve-in-valve registry. Circulation 126:2335–2344
48. Khatri PJ, Webb JG, Rodes-Cabau J et al (2013) Adverse effects
associated with transcatheter aortic valve implantation: a meta-
analysis of contemporary studies. Ann Intern Med 158:35–46
49. Bagur R, Dumont E, Doyle D et al (2010) Coronary ostia stenosis
after transcatheter aortic valve implantation. JACC Cardiovasc
Interv 3:253–255
50. GiustinoG,MontorfanoM, Chieffo A et al (2014) Tardive coronary
obstruction by a native leaflet after transcatheter aortic valve re-
placement in a patient with heavily calcified aortic valve stenosis.
JACC Cardiovasc Interv 7:e105–e107
51. Achenbach S, Delgado V, Hausleiter J, Schoenhagen P, Min JK,
Leipsic JA (2012) SCCT expert consensus document on computed
tomography imaging before transcatheter aortic valve implantation
(TAVI)/transcatheter aortic valve replacement (TAVR). J
Cardiovasc Comput Tomogr 6:366–380
52. Blanke P, Schoepf UJ, Leipsic JA (2013) CT in transcatheter aortic
valve replacement. Radiology 269:650–669
53. Hell MM, Biburger L, Marwan M et al (2017) Prediction of fluo-
roscopic angulations for transcatheter aortic valve implantation by
CT angiography: influence on procedural parameters. Eur Heart J
Cardiovasc Imaging 18:906–914
54. Blanke P, Soon J, Dvir D et al (2016) Computed tomography as-
sessment for transcatheter aortic valve in valve implantation: the
Vancouver approach to predict anatomical risk for coronary ob-
struction and other considerations. J Cardiovasc Comput Tomogr
10:491–499
55. Tanis W, Sucha D, Laufer W et al (2015) Multidetector-row com-
puted tomography for prosthetic heart valve dysfunction: is con-
comitant non-invasive coronary angiography possible before re-
do-surgery? Eur Radiol 25:1623–1630
56. Falk V,Walther T, Schwammenthal E et al (2011) Transapical aortic
valve implantation with a self-expanding anatomically oriented
valve. Eur Heart J 32:878–887
57. Foldyna B, Hansig M, Lucke C et al (2014) Access path angle in
transapical aortic valve replacement: risk factor for paravalvular
leakage. Ann Thorac Surg 98:1572–1578
Publisher’s note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
Affiliations
Marco Francone1 & Ricardo P. J. Budde2 & Jens Bremerich3 & Jean Nicolas Dacher4 & Christian Loewe5 & Florian Wolf5 &
Luigi Natale6 & Gianluca Pontone7 & Alban Redheuil8,9,10 & Rozemarijn Vliegenthart11 & Kostantin Nikolaou12 &
Matthias Gutberlet13 & Rodrigo Salgado14,15
1 Department of Radiological, Oncological and Pathological Sciences,
Sapienza University, Policlinico Umberto I, V.le Regina Elena 324,
00161 Rome, Italy
2 Department of Radiology & Nuclear Medicine, Erasmus MC,
Rotterdam, The Netherlands
3 Department of Radiology, University of Basel Hospital,
Basel, Switzerland
4 Department of Radiology, Normandie University, UNIROUEN,
INSERM U1096 – Rouen University Hospital, F
76000 Rouen, France
5 Division of Cardiovascular and Interventional Radiology,
Department of Biomedical Imaging and Image-Guided Therapy,
Medical University of Vienna, Vienna, Austria
6 Department of Radiological Sciences - Institute of Radiology,
Catholic University of Rome, “A. Gemelli” University Hospital,
Rome, Italy
Eur Radiol
7 Centro Cardiologico Monzino, IRCCS, Milan, Italy
8 Institute of Cardiometabolism and Nutrition (ICAN), Paris, France
9 Department of Cardiovascular and Thoracic, Imaging and
Interventional Radiology, Institute of Cardiology, APHP, Pitié-
Salpêtrière University Hospital, Paris, France
10 Laboratoire d’Imagerie Biomédicale, Sorbonne Universités, UPMC
Univ Paris 06, INSERM 1146, CNRS 7371, Paris, France
11 Department of Radiology, University of Groningen, University
Medical Center Groningen, Groningen, Netherlands
12 Department of Diagnostic and Interventional Radiology, University
of Tuebingen, Tübingen, Germany
13 Diagnostic and Interventional Radiology, University of Leipzig-
Heart Center, Leipzig, Germany
14 Department of Radiology, Antwerp University Hospital,
Antwerp, Belgium
15 Department of Radiology, Holy Heart Hospital, Lier, Belgium
Eur Radiol
